As the European market navigates mixed signals from major indices, with Germany's DAX showing modest gains and the UK experiencing economic contraction, investors are closely watching for opportunities amid potential interest rate adjustments by the ECB. In this climate of uncertainty, small-cap stocks with robust fundamentals can offer a compelling proposition for those seeking to uncover hidden value in Europe's diverse markets.

In recent weeks, the European market has seen mixed performance across major indices, with the pan-European STOXX Europe 600 Index ending slightly lower as investors processed various monetary policy decisions. Amid this backdrop of cautious optimism and economic recalibration, identifying stocks with strong fundamentals and growth potential becomes crucial for investors seeking opportunities in smaller-cap segments.

The cider brand has added a high-contrast NaviLens QR code to its cans.

BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.